Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.79
-0.4300-2.24%
Post-market: 19.150.3600+1.92%19:34 EDT
Volume:1.67M
Turnover:31.88M
Market Cap:1.98B
PE:-14.28
High:19.73
Open:19.39
Low:18.66
Close:19.22
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.66
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.30
PE(LYR):-2.64

Loading ...

Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says

Reuters
·
Aug 19

Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 10

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

MT Newswires Live
·
Aug 08

Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop

Simply Wall St.
·
Aug 07

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

MT Newswires Live
·
Aug 07

Oppenheimer Adjusts PT on Sarepta Therapeutics to $35 From $37, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CVS Health (CVS) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 06

Wedbush Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 06

Sarepta Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Sarepta reports Q2 adjusted EPS 64c, consensus 49c

TIPRANKS
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate

Benzinga Earnings
·
Aug 06

Sarepta Q2 FY26 Net Income Turns to USD 4.89 Million Loss; Revenue Drops 34% to USD 401.25 Million

Reuters
·
Aug 06

Sarepta Therapeutics Inc Expected to Post Earnings of 26 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Sarepta Files Form 3 for CEO, Director Michael Severino

Reuters
·
Jul 30

Sarepta Grants New CEO Severino Options for 2,224,342 Shares at $17.74, Plus 756,104 RSUs

Reuters
·
Jul 30

Sarepta Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 30

FDA Advisers Vote Against Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 30

Earning Preview: Sarepta Therapeutics Q2 revenue is expected to decrease by 31.25%, and institutional views are mixed leaning bullish

Earnings Agent
·
Jul 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Jul 28